Rekambys is used together with another medicine called cabotegravir to treat adults and adolescents aged 12 years and older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is used when the infection is under control with other HIV medicines. Adolescents must weigh at least 35 kg to take Rekambys. Rekambys contains the active substance rilpivirine.
Therapeutic Indication
### Therapeutic indication REKAMBYS is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) class.
Therapeutic Area (MeSH)
ATC Code
J05AG05
ATC Item
rilpivirine
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| rilpivirine | N/A | 利匹韦林 |
EMA Name
Rekambys
Medicine Name
Rekambys
Aliases
N/A